Rational Empiric Antibiotic Escalation Applied to Specific Patient Groups

2

1

3 Ranjeet Bamber

Department of Population Health Sciences, Bristol Medical School, Faculty of Health Sciences,
 University of Bristol, Bristol. UK

6 Brian Sullivan

7 Department of Population Health Sciences, Bristol Medical School, Faculty of Health Sciences,
 8 University of Bristol, Bristol. UK

9 Léo Gorman

10 Jean Golding Institute, University of Bristol, Bristol. UK

11 Winnie WY Lee

12 School of Cellular and Molecular Medicine, Faculty of Life Sciences, University of Bristol, Bristol. UK

13 Matthew B Avison

14 School of Cellular and Molecular Medicine, Faculty of Life Sciences, University of Bristol, Bristol. UK

15 Andrew W Dowsey

Department of Population Health Sciences, Bristol Medical School, Faculty of Health Sciences,University of Bristol

18 Philip Williams*

19 University Hospitals Bristol and Weston NHS Foundation Trust, Bristol Royal Infirmary, Bristol. UK

20

21 Running title: Rational Empiric Antibiotic Escalation Applied to Specific Patient Groups

Rational Empiric Antibiotic Escalation Applied to Specific Patient Groups

23

22

24 Abstract

25

26 Background

Clinicians commonly escalate empiric antibiotic therapy due to poor clinical progress, without
microbiology guidance. When escalating, they should take account of how resistance to an initial
antibiotic affects the probability of resistance to subsequent options. The term Escalation
Antibiogram (EA) has been coined to describe this concept. One difficulty when applying the EA
concept to clinical practice is understanding the uncertainty in results and how this changes for
specific patient subgroups.

33

34 Methods

35 A Bayesian model was developed to estimate antibiotic resistance rates in Gram-negative

36 bloodstream infections based on phenotypic resistance data. It provides an expected value

37 (posterior mean) with 95% credible interval to illustrate uncertainty, based on the size of the patient

38 subgroup, and estimates probability of inferiority between two antibiotics. This model can be

39 applied to specific patient groups where resistance rates and underlying microbiology may differ

- 40 from the whole hospital population.
- 41

42 Results

Rates of resistance to empiric first choice and potential escalation antibiotics were calculated for the
 whole hospitalised population based on 10,486 individual bloodstream infections, and for a range of

45 specific patient groups, including ICU, haematology-oncology, and paediatric patients. Differences in

46 optimal escalation antibiotic options between specific patient groups were noted.

47

48 Conclusions

49 EA analysis informed by our Bayesian model is a useful tool to support empiric antibiotic switches,

- 50 providing an estimate of local resistances rates, and a comparison of antibiotic options with a
- 51 measure of the uncertainty in the data. We demonstrate that EAs calculated for the whole
- 52 population cannot be assumed to apply to specific patient groups.

54	
55	Key Summary Points
56 57 58	 Clinicians commonly escalate empiric antibiotic therapy due to poor clinical progress, without microbiology guidance. When escalating, they should take account of how resistance to an initial antibiotic affects
59 60 61	 the probability of resistance to subsequent options. We describe a Bayesian model to guide empiric antibiotic escalation, based on local resistance data, that can be applied to small patient groups to predict rates of resistance
62 63 64	 with credible intervals. We demonstrate that the optimal antibiotic escalation for the whole population cannot be assumed to apply to specific patient groups, such as ICU or haematology patients.
65	

66 Introduction

67 In many countries, initial empiric antibiotic (AB) choices for the management of bacterial infections

- 68 are informed by local guidelines that in turn rely on an understanding of local phenotypic AB
- 69 resistance (ABR) patterns from blood culture isolates and other sample types. This initial AB
- 70 selection usually takes place within an hour of diagnosis of infection, and well before any
- 71 microbiological results are available. Furthermore, microbiological culture is a relatively insensitive
- technique. Even in patients with sepsis, only 30–50% will have a positive blood culture (1, 2). Hence,
- 73 it is also common for clinicians to empirically escalate AB therapy due to poor clinical progress in the
- absence of positive microbiology as a guide. While a poor clinical response may be due to a variety
- of factors, for example inadequate source control, it is the possibility of resistance to the first-choice
- 76 treatment that usually drives escalated AB therapy. In this context, therefore, it is not the local rate
- of resistance to the possible second-choice AB options that should be considered, but the rate of co-
- resistance to these agents in isolates resistant to the first AB choice. Though widely available, local
 phenotypic resistance data are an underused resource, and could be used to gain a better
- understanding of circulating co-resistance patterns and improve initial and escalated empiric AB
- 81 choice.

82 Some prior studies have explored this approach. As part of a medical decision support system tool

- 83 Zalounina et al (3) included prior AB treatments and local co-resistance data to guide subsequent AB
- 84 choice. Wong et al (4) investigated 3,280 Gram-negative bacillus (GNB) blood stream infections (BSI)
- 85 looking at the correlation coefficients between pairs of ABs, and the ABR profiles of subsets of
- 86 isolates resistant to a specified AB. They discussed examples of how these data could be used to
- 87 guide empiric AB escalation. They also suggested that local, unit based, ABR profiles and co-
- resistance patterns may be more useful than nationally collected data. Recently, Teitelbaum *et al* (5)
- took a similar approach looking at GNB BSIs. They coined the term "escalation antibiogram (EA)" to
- describe a profile of resistance to a set of ABs given resistance to an initial set of 12 ABs. Their local
 resistance patterns were stable over the period studied, including 6577 GNB BSI episodes, from 6
- 92 hospitals in their area allowing the data to be combined and averaged over time. They noted local
- 93 EAs were easy to generate, however they did not have the data available to subgroup by presumed
- 94 BSI source, and noted that the data may not generalise to specific patient groups.
- 95 One difficulty faced when applying the local EA concept to specific patient groups is the small
- 96 numbers involved. Moreover, rates of ABR may vary over time and can vary significantly from
- 97 country to country (6) and between regions within a country (7,8). Hence when attempting to
- 98 produce an EA applicable to certain patient groups, taking an average over several years will not
- always be appropriate, nor is it possible to get extra power by combining data from other regions
- 100 without diluting the desired effects of providing an EA based on local resistance data. Hence, our
- 101 objective was to develop and validate a model that allows tracking of variation in local ABR and co-
- resistance over time, and so maximises our ability to define an EA for specific patient groups. Our
- focus here was on ICU patients, haemato-oncology patients, patients with specific sources of BSI,
 and adults over 80 years. The Bayesian model scripts we developed for local use can be applied to
- 105 train the model for any region.
- 106
- 107

108 Methods

109 Data collection and cleaning

- 110 Data were collected from 3 NHS Trusts covering 4 hospitals in the Southwest of England serving a
- 111 population of approximately 1.5 million people (Royal United Hospital Bath NHS Foundation Trust,
- 112 University Hospitals Bristol & Weston NHS Foundation Trust, and North Bristol NHS Trust) which
- share a single laboratory information management system (Winpath Enterprise 7.23, Clinisys).
- 114 Positive blood cultures from all 4 hospitals where GNBs were isolated over a 6-year period, from
- 115 2017 to 2022, were included.
- 116 For each isolate, the ABR profile was determined by the European Committee on Antimicrobial
- 117 Susceptibility Testing (EUCAST) disc testing or by the Biomerieux Vitek 2 automated system. Direct
- disc sensitivities were obtained using EUCAST criteria following the Gram stain. In most cases (85%)
- isolates from a purity plate were tested using the Vitek 2 system the following day giving ABR
- 120 profiles for a wider range of ABs. Vitek results, when available, were used in preference to the initial
- disc testing. Results were expressed as "Sensitive", "Intermediate", or "Resistant". Following usual
- 122 clinical practices "Intermediate" and "Resistant" isolates were grouped together as non-susceptible,
- 123 which from now on we will refer to as "Resistant". Healthcare systems that have adopted EUCAST
- 124 V14 break points may elect to combine "Sensitive" and "Increase dose" as one group. When using a
- time series of categorical data, changes to the definition of a category e.g. a change in break points
- should be delt with by re-categorising the whole data set for affected organisms using MIC data and
- 127 new break points. Producing an R script to do this would be a trivial task.
- 128 Repeat samples from the same patient with an indistinguishable isolate (Species ID and ABR profile)
- 129 which occurred within 1 year were removed. Following de-duplication, we had 10,486 GNB BSIs over
- 130 the 6-year period. For *Pseudomonas* spp. and *Stenotrophomonas* spp. isolates, ABs that are not
- 131 tested due to assumed intrinsic resistance were automatically set to Resistant.
- 132 From 2020 onwards, the presumed source of BSI was recorded in a two-level hierarchical system,
- 133 with the highest level consisting of the following groups: central nervous system, cardiac, gastro-
- 134 intestinal, urine/renal, bone/joint, skin/soft tissue, respiratory, reproductive tract, mouth/head and
- neck, line infection, contaminant, unknown, or other. Data were extracted every 3 months and
- 136 missing data filled in by case note review.
- 137

138 Technical details of the Bayesian model

- 139 A Bayesian model was developed that estimates ABR rate in GNB BSI and provides an expected value
- 140 (posterior mean) and 95% credible interval of ABR rate for a given AB at any chosen time point 141 within the 6 years of data collected
- 141 within the 6 years of data collected.
- 142 Formally, we use a generalised additive model with a Bernoulli likelihood and logit link function for
- 143 the binary outcome (Sensitive/Resistant) and a time varying covariate modelled by a penalised thin-
- 144 plate regression spline. The model generates a series of "credible" curves to fit the resistance data,
- each with the same probability of representing the true rate given the inherent uncertainty. To avoid
- 146 overfitting, an integrated penalisation term adaptively smooths the curves given the level of
- evidence. The model is implemented with the R package 'brms' (9), which adopts the Stan platform
- 148 for Bayesian inference with Hamiltonian Monte-Carlo sampling (10). Four chains are run for 4,000
- 149 iterations, with the first 50% discarded as warm-up, leading to 8,000 plausible curves fitting the data.

- Statistics such as mean and credible intervals can be directly computed from samples of the curvesat the required times.
- 152 Resistance rates between two groups or time points are compared by subtracting one set of curves
- from another, allowing us to calculate the posterior probability of an increase (PPI) or decrease
- 154 (PPD) in resistance over time or the posterior probability of inferiority (PPInf), or superiority (PPSup)
- 155 between two AB options. In keeping with the philosophy of a Bayesian approach we do not attempt
- to define what probability of difference or superiority is significant, but to simply provide that
- 157 probability of a difference with the 95% credible interval.
- 158
- 159

160 Results & Discussion

161 Changes in ABR over time

Over a 6-year period between 2017 to 2022, ABR rates were calculated for deduplicated GNB BSI in
 patients across our local hospitals (n=10,486). An example of this output, piperacillin/tazobactam
 resistance in haemato-oncology patients is reported (Fig. 1).

165 The resistance rate increased for meropenem (1.5% to 2.2%, PPI = 88.7%), but reduced slightly (See

supplementary material) in all other ABs studied (piperacillin/tazobactam (Tazocin), gentamicin,

amikacin, cefotaxime, ceftazidime, ciprofloxacin, trimethoprim/sulfamethoxazole (Cotrimoxazole)

and amoxicillin/clavulanate (Coamoxiclav). The reductions ranged from 2.3% in Ceftazidime (Fig. 2a)

169 (PPD = 94.3%), to 6.9% in trimethoprim/sulfamethoxazole resistance rate (Fig. 2b) (PPD = 98.5%).

170 This larger reduction in resistance may be related to the removal of trimethoprim as first-line

treatment for lower urinary tract infection in local community guidelines from April 2017, which

- resulted in a reduction in trimethoprim resistance in *E. coli* from community urine samples (11).
- 173

176 Informing empiric AB choice in specific patient groups

177 When examining resistance to specific ABs in specific patient populations, the 95% CI tends to widen

178 due to the reduced sample size. For example, piperacillin/tazobactam resistance in GNB BSIs in ICU

patients has a much wider 95% CI compared to the whole hospital data, as the former is based on

180 695 positive blood cultures compared to 10,486 for the latter (Fig. 3a, 3b). Over time,

181 piperacillin/tazobactam resistance rates have increased for ICU patients and haemato-oncology

patients (fig. 3b, 3c), while reducing over the whole hospital population (fig. 3a). Clearly, therefore,

using the mean resistance rate for piperacillin/tazobactam over the 6-year period to inform empiric

AB choice would underestimate the current resistance rate in the ICU and haemato-oncology

populations, while using only the last year or few months data would be excessively influenced by

186 random month-to-month variation in small patient groups. Our model overcomes this issue as the

- 187 time series data allows us to estimate current ABR rates, and the uncertainty, while the model
- 188 borrows information from the earlier data.

189 Following this example, the posterior means between piperacillin/tazobactam resistance rates in

190 GNB BSI isolates from the ICU population and the whole hospital population are different (27.4% vs

191 13.4%, respectively), and the 95% CIs do not overlap, suggesting this difference is reliable. The

192 probability that ICU patients have higher resistance rates can be computed simply as the proportion

193 of curves that are higher in models of the ICU population than the whole hospital population at this

timepoint, in this case, PPI = 99.9%.

195 In contrast, the difference between the posterior mean piperacillin/tazobactam resistance rates for

196 BSI GNBs from ICU and haemato-oncology patients is small (27.4% vs 30.7%) and there is a

197 considerable overlap in the 95% CIs. This is reflected in the calculated posterior probability of 67.5%

198 that piperacillin/tazobactam resistance rate is lower in the ICU population compared with the

haemato-oncology population (e.g., PPD = 67.5%) or conversely there is a 32.5% probability that the

200 resistance rate is greater in ICU patients than in haemato-oncology patients (e.g., PPI = 32.5%).

The situation for ceftazidime is similar, with a higher (and increasing) rate of resistance in both ICU and haemato-oncology patients compared to the whole hospital population. Both ICU and haemato-

203 oncology patients have a higher proportion of potentially AmpC hyper-producing "SPACE" (Serratia,

204 Pseudomonas, Acinetobacter, Citrobacter & Enterobacter) isolates compared to the whole

205 population (ICU 38% vs 25%, PPD = 99.3%) and haemato-oncology (30% vs 25%, PPD = 87.0%) which

206 explains a proportion of the higher resistance rates.

207 The increase in ceftazidime resistance over time is likely greater in haemato-oncology patients

208 (15.2% to 24.5%, PPI = 89.4%) than ICU (17.6% TO 20%, PPI = 66.3%), and is due to both increased

resistance in non-*E. coli* isolates include in SPACE organisms, (Figure 4) and in an increase in the

210 proportion of non-*E. coli* isolates (*E. coli* reduced from 44% to 35%, PPD = 82%, in haemato-

211 oncology, while in ICU the proportion of *E. coli* remained at 27%)

212

214 Calculating an escalation antibiogram (EA) for specific patient groups

- To calculate an EA, our Bayesian model is applied for any given second-choice AB to all isolates
- 216 resistant to the first-choice AB. Table 1 reports these data for the whole hospital population express
- as a most likely rate of resistance with 95% credible intervals. In this population if moving away from
- 218 piperacillin/tazobactam we would predict 27% (95% Cl 18 to 24) if moving to gentamicin and 31%
- 219 (95% CI 21 to 40) if switching to ciprofloxacin.
- 220 We can also calculate the probability of inferiority (PPInf) between pairs of alternative antibiotics.
- 221 This is shown in figure 5 using data for ICU patients assuming piperacillin/tazobactam resistance.
- 222 When making a clinical decision on antibiotic selection, the probability of inferiority is only useful
- 223 when both alternatives have a suitably low rate of resistance.
- 224 It is worth noting that GNB BSI resistance rates to meropenem are low in this region (~2%), where
- 225 meropenem is invariably superior as an empiric choice. Our analysis has therefore focused on other
- ABs as meropenem-sparing alternatives. Similarly within our region, resistance rates to newer
- 227 antibiotics such as Cetazidime-Avibactam or Meropenem-Vaborbactam are currently too low to
- allow inclusion in our analysis.
- 229

230 Escalation Antibiogram Example 1

- 231 In severe Gram-negative infections, two of the most commonly used β -lactams are
- 232 piperacillin/tazobactam (first-line AB for neutropenic sepsis and widely used in ICU) and ceftazidime
- 233 (a useful alternative to piperacillin/tazobactam especially in non-severe penicillin allergy). In our
- region, piperacillin/tazobactam and ceftazidime resistance rates among GNB BSIs are similar: 13.4%
- 235 (95% CI 10.8 to 16.1) and 10.6% (95% CI 8.9 to 12.7) respectively. The merits of the addition of an
- aminoglycoside to a β -lactam has been much debated (12,13) but will inevitably depend on local
- resistance and co-resistance rates. We will look at the effect of resistance to piperacillin/tazobactam
- and ceftazidime on the probability of resistance to gentamicin (our mostly widely used
- aminoglycoside) and amikacin (which is rarely used locally) in two specific patient groups, ICU
- 240 patients and haemato-oncology and compare these results with those generated from the whole
- 241 hospital population.
- 242 When comparing a wide group of second line options when adding to, or switching from
- 243 piperacillin/tazobactam or ceftazidime (Tables 2 and 3), ABs are ordered in preference for whole
- 244 hospital populations, showing the percent resistant with 95% CI, and with the PPInf to that in the
- column on its left in the table. Values under 50% indicate the AB is superior to that on its left.
- Resistance rates to both aminoglycosides are much higher in isolates resistant to either ceftazidime or piperacillin/tazobactam, with resistance rates vary from 14% to 39% depending on the patient
- group and antibiotic combinations compared to 3% to 13% aminoglycoside resistance in all isolates.
- 249 Within the whole hospital population, amikacin remains the best option for patients switching from 250 either ceftazidime or piperacillin/tazobactam, with a 97% & 95% probability of superiority compared 251 to gentamicin, although there is a greater relative increase in amikacin resistance compared to 252 gentamicin (see Tables 2 and 3).
- 253
- 254 Within the ceftazidime and piperacillin/tazobactam resistant isolates, both the ICU and haemato-
- 255 oncology populations differ from the whole hospital population with lower rates of aminoglycoside
- resistance in ICU, and higher rates of resistance in haemato-oncology patients (Fig 6). Within ICU

- 257 patients amikacin is likely to be superior, PPSup = 69.8% if switching from piperacillin/tazobactam
- and PPSup = 71% if switching from ceftazidime. For the haemato-oncology patients there is little
- 259 difference between amikacin and gentamicin, (PPSup = 52%) although there is a noticeably higher
- 260 rate of resistance for both when switching from ceftazidime compared to piperacillin/tazobactam
- 261 (also see plots in supplementary material).
- 262

A difference between whole population and ICU or haemato-oncology populations are seen in a range of other antibiotics. Within the ICU patients, ciprofloxacin, trimethoprim/sulphamethoxazole and gentamicin have a similar probability of sensitivity, which is noticeably lower than in the whole hospital population. While within the haemato-oncology cohort, resistance rates to amikacin and gentamicin are higher than in the general population, and resistance rates to ciprofloxacin and trimethoprim/sulphamethoxazole are similar, despite both being used in some prophylaxis regimes. The resistance rates for all options are high (30-40%), so in a neutropenic patient, meropenem

270 would be a more suitable alternative.

It is clear therefore, that sub-population analysis will be required by those intending to apply the EAin clinical practice.

273

274 Escalation Antibiogram Example 2

Having noted how changes in resistance over time differ between species, for example cefotaxime
resistance in *E. coli* and non-*E. coli* (See supplementary material), we confirmed that this effect was
also present in piperacillin/tazobactam resistant isolates. (Fig 7). We then looked at two clinical
groups with a high proportion of *E. coli* infections (patients over 80 years old and patients with a
urinary source of infection) to determine if they differed from the whole hospital population (Tables
4 and 5).

Overall, the proportion of BSI caused by *E. coli* has very likely decreased from 59.1% (95%CI 54.9 to 63.8) at the start of 2017 to 51.4% (95%CI 47.1 to 55.5, PPD = 99.6%) at the end of 2022. Within patients over 80 years old, and patients with a BSI of urine or renal tract source we have seen a similar decrease in the proportion of *E. coli* BSI, to a current rate of 59.7% (95%CI 54.3 to 64.4) from 68% (95%CI 63.5 to 72.9, PPD = 99.3%) and 57.8 (95%CI 48.5 to 64.4) from 65.6% (95%CI 58.2 to 71.9, PPD = 94.5%) respectively.

- 287 When switching from piperacillin/tazobactam (Table 4) it appears that amikacin is the best option,
- but in circumstances where an aminoglycoside could not be used (e.g., poor renal function),
- 289 cefotaxime is comparable to ciprofloxacin and superior to co-trimoxazole for urinary source
- 290 infections.

291 We would not usually think of empirically changing from piperacillin/tazobactam to cefotaxime, as

- the former is usually considered to be broader spectrum, and it is often assumed that resistance to
- 293 piperacillin/tazobactam would also confer resistance to 3rd generation cephalosporins. While AmpC
- enzymes can confer resistance to both classes, when ESBL-producing isolates are reported as
 piperacillin/tazobactam resistant, this can be due to a range of β-lactamases which are not routinely
- identified in clinical isolates. β-Lactamases including OXA-1, inhibitor resistant TEM, or the high
- 297 levels of TEM-1 can result in piperacillin/tazobactam resistance, independently of 3rd generation
- 298 cephalosporins resistance (14).

- Assuming ceftazidime resistance (Table 5) showed that amikacin is clearly superior in the urinary
- source group, whereas for over 80s, amikacin or gentamicin are broadly comparable. Due to the high
- 301 resistance rates of co-trimoxazole and ciprofloxacin, meropenem would be suitable if an
- 302 aminoglycoside could not be used.

303 Conclusions

- 304 Failure of empiric AB therapy is a regularly encountered clinical problem for infection speicialist. EA
- analysis informed by our Bayesian model is a useful tool to support clinician decision making in
- 306 escalation of empiric AB therapy for the deteriorating patient when microbiology results are not
- available. The model produces a mean resistance rate, with 95% credible intervals for any AB option,
 and allows the calculation of a posterior probability that one AB choice is superior to another based
- 309 on local ABR patterns.
- 310 The clinical application of this model requires the use of data appropriate to the patient group being
- 311 treated and an understanding of the uncertainty in the data this uncertainty will increase when
- 312 applying the concept to relatively small patient groups. We conclude that within our region, the
- 313 application of whole hospital data to groups with different underlying presentations and AB
- 314 exposures such as haemato-oncology patients or paediatric patients is not appropriate. To overcome
- this shortcoming of simple EA analysis, we have focused on patient groups that can be determined
- before blood culture results are known, based on age, presumed source of infection, ICU patients or
- haemato-oncology patients. We have avoided the use of species-specific antibiograms, preferring to
- 318 use those based on the mix of species found in the patient group under consideration. We note the
- differences in species proportions between groups appears to explain a significant amount of theresistance difference.
- We anticipate that the results of our EA analysis in a given institution would be utilised by infection
- 322 specialists, rather than general clinicians, to avoid potentially inappropriate AB choices, such as the 323 use of aminoglycosides as a single agent where this contraindicated, and to ensure that alternative
- 324 reasons for poor response to empiric AB therapy (e.g. lack of source control) are considered.
- 325 Our model can be easily introduced in any institution using the freely available software package, R.
- 326 It requires only appropriately cleaned and de-duplicated ABR data which, in many cases, is already
- 327 generated regularly to inform antimicrobial guideline development. This process of gathering data
- 328 can also be automated, as in our centre, to further reduce the associated workload, and the model
- 329 can be run as often as indicated by local demands. We suggest that this model is suitable for
- 330 widespread adoption across institutions where infection specialists are making antimicrobial
- escalation decisions in the absence of helpful microbiological results.

332 Ethics

- 333 This was a retrospective study using anonymised data already collected as part of routine clinical
- care. This project was approved by Public Health England's Research Ethics and Governance Group(REGG).
- 336

337 Funding

338 P.W., M. B. A. & A.W.D. were supported by Medical Research Council grant MR/T005408/1

R.B., & B.S. were supported by Health Data Research UK via the Better Care Partnership Southwest(HDR CF0129).

- 341 W.W.Y.L. received a scholarship from the Medical Research Foundation National PhD Training
- 342 Program in Antimicrobial Resistance Research (MRF-145-0004-TPG-AVISO).
- 343

344 Transparency declarations

- 345 All authors confirm that they have no conflicts of interest to declare.
- 346

347 Author Contributions

- 348 Conceived the Study and Obtained Funding: P.W., A.W.D., M.B.A.
- Cleaning and Analysis of Data: R.B., B.S., L.G., W.W.Y.L., A.W.D., P.W.
- 350 Initial Drafting of Manuscript: P.W., M.B.A.
- 351 Corrected and Approved Manuscript: All authors

352 References


- 1. Scheer, C. S., Fuchs, C., Gründling, M., Vollmer, M., Bast, J., Bohnert, J. A., ... & Kuhn, S. O. (2019).
- Impact of antibiotic administration on blood culture positivity at the beginning of sepsis: a
 prospective clinical cohort study. *Clinical Microbiology and Infection*, *25*(3), 326-331.
- 356
- 2. Murray, P. R., & Masur, H. (2012). Current approaches to the diagnosis of bacterial and fungal
 bloodstream infections for the ICU. Critical care medicine, 40(12), 3277.
- 359 3. Zalounina, A., Paul, M., Leibovici, L., & Andreassen, S. (2007). A stochastic model of susceptibility
- to antibiotic therapy—the effects of cross-resistance and treatment history. Artificial Intelligence in
 Medicine, 40(1), 57-63.
- 362 4. Wong, P. H., von Krosigk, M., Roscoe, D. L., Lau, T. T., Yousefi, M., & Bowie, W. R. (2014).
- Antimicrobial co-resistance patterns of gram-negative bacilli isolated from bloodstream infections: a longitudinal epidemiological study from 2002–2011. BMC infectious diseases, 14(1), 1-10.
- 5. Teitelbaum, D., Elligsen, M., Katz, K., Lam, P. W., Lo, J., MacFadden, D., ... & Daneman, N. (2022).
- 366 Introducing the Escalation Antibiogram: A Simple Tool to Inform Changes in Empiric Antimicrobials in 367 the Nonresponding Patient. Clinical Infectious Diseases, 75(10), 1763-1771.
- 6. Murray, C. J., Ikuta, K. S., Sharara, F., Swetschinski, L., Aguilar, G. R., Gray, A., ... & Tasak, N. (2022).
 Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. The Lancet,
 399(10325), 629-655.
- 371 7. Quarterly laboratory surveillance of acquired carbapenemase-producing Gram-negative bacteria372 in England: October 2020 to September 2022
- 373 <u>https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file</u>
 374 /1135930/hpr0223-CPGNB-Q32022-v2.pdf
- 8. English surveillance programme for antimicrobial utilisation and resistance (ESPAUR) Report 2021to 2022
- 377 <u>https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file</u>
 378 /1118310/ESPAUR-report-2021-to-2022.pdf


- 379 9.. Bürkner P (2017). "brms: An R Package for Bayesian Multilevel Models Using Stan." Journal of
 380 Statistical Software, 80(1), 1–28. doi:10.18637/jss.v080.i01.
- 381 10. Stan platform for Bayesian inference with Hamiltonian Monte-Carlo sampling. Stan Development
- Team. 2022. Stan Modeling Language Users Guide and Reference Manual, VERSION. <u>https://mc-</u>
 <u>stan.org</u>
- 11. Hammond, A., Stuijfzand, B., Avison, M. B., & Hay, A. D. (2020). Antimicrobial resistance
 associations with national primary care antibiotic stewardship policy: Primary care-based, multilevel
- analytic study. PloS one, 15(5), e0232903.

- 12.Paul, M., Soares-Weiser, K., & Leibovici, L. (2003). β lactam monotherapy versus β lactamaminoglycoside combination therapy for fever with neutropenia: systematic review and metaanalysis. Bmj, 326(7399), 1111.
- 13. Tang, Y., Wu, X., Cheng, Q. *et al.* Inappropriate initial antimicrobial therapy for hematological
- malignancies patients with Gram-negative bloodstream infections. *Infection* 48, 109–116 (2020).
 https://doi.org/10.1007/s15010-019-01370-x

- 395 <u>14)</u>: Davies TJ, Stoesser N, Sheppard AE, Abuoun M, Fowler P, Swann J, Quan TP, Griffiths D,
- 396 Vaughan A, Morgan M, Phan HTT, Jeffery KJ, Andersson M, Ellington MJ, Ekelund O, Woodford N,
- 397 Mathers AJ, Bonomo RA, Crook DW, Peto TEA, Anjum MF, Walker AS. Reconciling the Potentially
- 398 Irreconcilable? Genotypic and Phenotypic Amoxicillin-Clavulanate Resistance in Escherichia coli.
- 399 Antimicrob Agents Chemother. 2020 May 21;64(6):e02026- 19. doi: 10.1128/AAC.02026-19. PMID:
- 400 32205351; PMCID: PMC726950
- 401
- 402
- 403
- 404
- 405
- 406
- 407
- 408
- 409
-
- 410
- 411
- 412
- 413
- 414








representing the number of samples in the data. (Middle) A 'spaghetti plot' of a random selection of 419

splines fitted to the data that make up the model, and (Bottom) a 'ribbon' plot showing the inferred 420

421 posterior mean (black line) with the 66% and 95% credible interval (dark and light blue shaded

422 areas) with the quarterly rates shown as dots.



 425
 Figure 2. All deduplicated GNB BSI isolates (n=10486) (a) Percent Resistance to Ceftazidime reduces

 426
 from 12.9% (95% CI 10.9 to 15.3) in 2017 to 10.6% (95% CI 8.8 to 12.9) in 2022. (b) % Resistance to

 427
 trimethoprim/sulfamethoxazole reduces from 32.9% (95% CI 28.3 to 36.4) in 2017 to 26.0% (95% CI

428 22.7 to 29.4) in 2022




Figure 3. Piperacillin/tazobactam resistance for all patients (Top) compared to ICU patients (Middle)
435 and haemato-oncology patients (bottom)





Figure 4. Percent resistance to ceftazidime in all isolates (left column) and non-E coli isolates (right
 column) located in either (Top Row) ICU (Bottom row) or Haematology/Oncology.





454 *Figure 5.* For ICU patients with assumed resistance to piperacillin/tazobactam. The estimated

455 resistance rate to 6 antibiotic options with the 66% and 95% credible interval is shown on the left.


456 The centre and right plots each show a head to head comparison between one antibiotic (Amikacin

457 or Ciprofloxacin) and the other five antibiotics. This gives the estimated difference in probability of

458 resistance, for example, there is 41% probability of higher resistance in amikacin compared to

459 ciprofloxacin (right), only marginally favouring amikacin, while there is an 81% probability of higher

460 resistance in co-trimoxazole compared to ciprofloxacin (right) favouring the use of ciprofloxacin.



461


462 **Figure 6.** Percent Resistance to gentamicin assuming piperacillin/tazobactam resistance in (Top) all


463 isolates 27.0% (95% CI 18.5 to 34.5), (Middle) ICU 19.2% (95% CI 7.1 to 37.0), (Bottom) haemato-

464 oncology 33.5% (95% CI 14.6 to 57.5)









471 (95%Cl 11 to 28) PPD = 95.5%

Second Choice Antibiotic Meropenem

er 2.5% Cl NA 0.07
0.07
0.07
0.08
0.05
0.07
0.11
0.03
0.01
0.02

Second Choice Antibiotic Pipercillin/Tazobactam

Tiperenini/Tazobactani				
Upper 97.5% CI	Lower 2.5% Cl			
0.83	0.47			
NA	NA			
0.68	0.43			
0.44	0.24			
0.36	0.22			
0.58	0.33			
0.89	0.44			
0.32	0.21			
0.45	0.23			
0.23	0.13			
	Upper 97.5% Cl 0.83 NA 0.68 0.44 0.36 0.58 0.58 0.89 0.32 0.45			

Second Choice Antibiotic Ceftazidime

	Centazialine		
	Posterior Mean	Upper 97.5% Cl	Lower 2.5% Cl
Meropenem	0.62	0.78	0.43
Pip.Taz	0.47	0.56	0.38
Ceftazidime	NA	NA	NA
Cefotaxime	0.51	0.59	0.44
Cefuroxime	0.36	0.42	0.31
Gentamicin	0.45	0.59	0.35
Amikacin	0.67	0.88	0.47
Coamoxiclav	0.2	0.24	0.17
Ciprofloxacin	0.41	0.5	0.33
Cotrimoxazole	0.18	0.22	0.14
	Pip.Taz Ceftazidime Cefotaxime Cefuroxime Gentamicin Amikacin Coamoxiclav Ciprofloxacin	Meropenem0.62Pip.Taz0.47CeftazidimeNACefotaxime0.51Cefuroxime0.36Gentamicin0.45Amikacin0.67Coamoxiclav0.2Ciprofloxacin0.41	Posterior MeanUpper 97.5% ClMeropenem0.620.78Pip.Taz0.470.56CeftazidimeNANACefotaxime0.510.59Cefuroxime0.360.42Gentamicin0.450.59Amikacin0.670.88Coamoxiclav0.20.24Ciprofloxacin0.410.5

Second Choice Antibiotic Cefotaxime

Posterior Mean	Upper 97.5% Cl	Lower 2.5% Cl
0.89	0.99	0.62
0.44	0.53	0.33
0.78	0.86	0.67
NA	NA	NA
0.57	0.62	0.52
0.45	0.59	0.35
0.74	0.9	0.58
0.32	0.37	0.27
0.42	0.52	0.33
0.42	0.49	0.34

Second Choice Antibiotic Cefuroxime

	Cefuroxime		
	Posterior Mean	Upper 97.5% Cl	Lower 2.5% Cl
Meropenem	0.95	1	0.82
Pip.Taz	0.63	0.71	0.53
Ceftazidime	0.97	0.99	0.93
Cefotaxime	0.99	1	0.98
Cefuroxime	NA	NA	NA
Gentamicin	0.58	0.71	0.47
Amikacin	0.81	0.94	0.67
Coamoxiclav	0.53	0.59	0.47
Ciprofloxacin	0.63	0.74	0.54
Cotrimoxazole	0.5	0.57	0.43

Second Choice Antibiotic Gentamicin

Posterior Mean	Upper 97.5% Cl	Lower 2.5% Cl
0.45	0.64	0.28
0.27	0.34	0.18
0.33	0.41	0.25
0.21	0.27	0.16
0.15	0.2	0.12
NA	NA	NA
0.61	0.78	0.41
0.13	0.17	0.1
0.35	0.43	0.27
0.17	0.22	0.12

Second	Choice	Antibiotic
	Amika	in

		Allikacili		
		Posterior Mean	Upper 97.5% Cl	Lower 2.5% Cl
	Meropenem	0.41	0.62	0.23
J	Pip.Taz	0.18	0.25	0.11
Initial Choice Antibiotic	Ceftazidime	0.2	0.3	0.12
ntib	Cefotaxime	0.16	0.23	0.1
β	Cefuroxime	0.1	0.15	0.06
hoid	Gentamicin	0.23	0.37	0.11
ייכו	Amikacin	NA	NA	NA
nitic	Coamoxiclav	0.06	0.09	0.03
2	Ciprofloxacin	0.16	0.25	0.08
	Cotrimoxazole	0.05	0.09	0.02

Second Choice Antibiotic	C
Coamoxiclav	

Posterior Mean	Upper 97.5% Cl	Lower 2.5% Cl
0.99	1	0.94
0.91	0.96	0.84
0.87	0.92	0.8
0.9	0.94	0.83
0.85	0.89	0.8
0.82	0.89	0.73
0.85	0.94	0.71
NA	NA	NA
0.72	0.8	0.64
0.78	0.82	0.73

Second Choice Antibiotic Ciprofloxacin

		Сірготіохасіп							
		Posterior Mean	Upper 97.5% Cl	Lower 2.5% Cl					
	Meropenem	0.23	0.45	0.09					
J	Pip.Taz	0.31	0.4	0.21					
ioti	Ceftazidime	0.45	0.54	0.35					
Initial Choice Antibiotic	Cefotaxime	0.29	0.38	0.22					
e A	Cefuroxime	0.24	0.31	0.19					
hoic	Gentamicin	0.55	0.66	0.43					
al Cl	Amikacin	0.66	0.86	0.41					
nitic	Coamoxiclav	0.17	0.21	0.13					
-	Ciprofloxacin	NA	NA	NA					
	Cotrimoxazole	0.24	0.3	0.19					

Second Choice Antibiotic Cotrimoxazole

Posterior Mean	Upper 97.5% Cl	Lower 2.5% Cl
0.58	0.75	0.39
0.37	0.45	0.27
0.43	0.53	0.33
0.67	0.75	0.58
0.46	0.52	0.39
0.58	0.71	0.45
0.45	0.64	0.24
0.44	0.48	0.39
0.58	0.67	0.49
NA	NA	NA

Table 1. Posterior mean resistance estimates with 95% credible intervals for the whole hospital
477 population. Tables for haemato-oncology, paediatrics, GI or urinary source infections are in the

477 population. Tables for haemato-oncology, paediatrics, GI or urinary source infections are in the478 supplementary material.

Pip/Taz Resistant	Amikacin	Gentamicin	Ciprofloxacin	Co-trimoxazole	Cefotaxime	Ceftazidime
All (% R with Cl)	18% (11 to 25)	27% (18 to 34)	31% (21 to 40)	37% (28 to 45	44% (33 to 53)	47% (37 to 55)
All (% inferior)		95.0%	73.7%	81.9%	82.8%	72.5%
ICU (% R with CI)	14% (4 to 33)	19% (7 to 37)	17% (6 to 33)	23% (10 to 40)	65% (41 to 83)	63% (46 to 84)
ICU (% inferior)		69.8%	39.4%	74.6%	99.9%	45.5%
Haem (% R with CI)	31% (9 to 55)	32% (7 to 57)	31% (8 to 62)	42% (16 to 74)	58% (32 to 81)	62% (34 to 84)
Haem (% inferior)		52.8%	49.5%	71.5%	81.7%	41.2%

Table 2. Escalation antibiogram for piperacillin/tazobactam (pip/taz) resistant isolates showing
resistance rate and the posterior probability of inferiority (PPInf) to the antibiotic choice to the
choice to the immediate left (e.g., Gentamicin v. Amikacin, Ciprofloxacin v. Gentamicin, etc.) across
the whole hospital and in subgroups from ICU and Haematology/Oncology. Numbers in brackets

489 indicate upper and lower bounds for the 95% credible interval.

490

Ceftazidime	Amikacin	Gentamicin	Co-trimoxazole	Ciprofloxacin	Pip/Taz	Cefotaxime
Resistant						
All (% R or I)	21% (12 to 30)	33% (24 to 41)	43% (33 to 52)	45% (35 to 54)	57% (43 to 687)	78% (67 to 86)
All (% inferior)		97.2%	94.4%	62.4%	92.4%	99.7%
ICU (% R or I)	17% (4 to 42)	24% (7 to 44)	27% (10 to 49%)	28% (11 to 52)	86% (66 to 98)	88% (70 to 98
ICU (% inferior)		71.0%	58.3%	53.5%	99.9%	59.7%
Haem (% R or I)	38% (18 to 62)	39% (19 to 64)	39% (16 to 64)	35% (13 to 61)	77% (54 to 92)	88% (69 to 98)
Haem (% inferior)		52.3%	50.1%	40.1%	99.2%	84.6%

491 Table 3. Escalation antibiogram for Ceftazidime resistant isolates showing resistance rate and the

492 PPInf to the antibiotic choice to the choice to the immediate left (e.g., Gentamicin v. Amikacin,

493 Ciprofloxacin v. Gentamicin, etc.) across the whole hospital and in subgroups from ICU and

Haematology/Oncology. Numbers in brackets indicate upper and lower bounds for the 95% credibleinterval.

496

Pip/Taz Resistant	Amikacin	Gentamicin	Ciprofloxacin	Co-trimoxazole	Cefotaxime	Ceftazidime
All (% R or I)	18% (11 to 25)	27% (18 to 34)	31% (21 to 40)	37% (28 to 45	44% (33 to 53)	47% (378 to 55)
All (% inferior)		95.0%	73.7%	81.9%	82.8%	72.5%
Over 80 (% R or I)	16% (5 to 29)	19% (7 to 34)	39% (22 to 54)	39% (25 to 55)	37% (20 to 53)	43% (28 to 56)
Over 80 (% inferior)		60.0%	94.6%	48.2%	43.6%	67.3%
U/R Source (% R or I)	13% (3 to 27)	29% (13 to 46)	33% (16 to 53)	39% (22 to 59)	29% (15 to 47)	36% (19 to 59)
U/R Src (% inferior)		93.2%	63.5%	68.3%	20.9%	68.4%

Table 4. Escalation antibiogram for piperacillin/tazobactam resistant isolates showing resistance rate
and the posterior probability of inferiority (PPInf) to the antibiotic choice to the the choice to the
immediate left (e.g., Gentamicin v. Amikacin, Ciprofloxacin v. Gentamicin, etc.). Data for whole
hospital, and subgroups of patients over 80 years, and infections with urine/renal source. Numbers

501 in brackets indicate upper and lower bounds for the 95% credible interval.

502

Ceftazidime Resistant	Amikacin	Gentamicin	Co-trimoxazole	Ciprofloxacin	Pip/Taz	Cefotaxime
All (% R or I)	21% (12 to 30)	33% (24 to 41)	43% (33 to 52)	45%(35 to 54)	57% (43 to 687)	78% (67 to 86)
All (% inferior)		97.2%	94.4%	62.4%	92.4%	99.7%
Over 80 (% R or I)	21% (9 to 35)	25% (11 to 40)	44% (27 to 60)	44% (24 to 63)	49% (33 to 66)	77% (62 to 88)
Over 80 (% inferior)		68%	94.3%	52.7%	60.9%	99.3%
U/R Source R or I)	13% (2 to 33)	34% (15 to 54)	48% (24 to 72)	57% (35 to 76)	49% (29 to 72)	80% (55 to 96)
U/R Src (% inferior)		93.7%	80.8%	72.2%	28.3%	96.6%

503 Table 5. Escalation antibiogram for ceftazidime resistant isolates showing resistance rate and the

posterior probability of inferiority (PPInf) to the antibiotic choice to the the choice to the immediate

505 left (e.g., Gentamicin v. Amikacin, Ciprofloxacin v. Gentamicin, etc.). Data for whole hospital,

and subgroups of patients over 80 years, and infections with urine/renal source. Numbers in brackets

507 indicate upper and lower bounds for the 95% credible interval.